SOHO 2022 Tenth Annual Meeting

 

SOHO 2022 Tenth Annual Meeting
Avatar

SOHO 2022: Allogeneic CAR T-Cells in ALL

By SOHO 2022 Tenth Annual Meeting FEATURING Nitin Jain
By SOHO 2022 Tenth Annual Meeting FEATURING Nitin Jain
14 views
October 13, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter
Leukemia
06:06
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Characteristics of Patients With Myelofibrosis Taking Rux…

Feat. L. Masarova
16:50
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Role of ddPCR in CML Today

Feat. J. Radich, S. Soverini
15:48
SOHO 2022 Tenth Annual Meeting

SOHO 2022: State of the Art in CML

Feat. M. Deininger, G. Saglio
08:51
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Long-Term Outcomes After Haplo-SCT for Hematologic Malign…

Feat. S. Saengboon
09:22
SOHO 2022 Tenth Annual Meeting

GLOW Study - First Prospective Data on MRD Outcomes After Fixed-Dura…

Feat. C. Owen
09:54
SOHO 2022 Tenth Annual Meeting

SOHO 2022 Next Questions: CML

Feat. T. Hughes
08:27
SOHO 2022 Tenth Annual Meeting

SOHO 2022 Next Questions: CLL

Feat. F. Cymbalista
12:33
SOHO 2022 Tenth Annual Meeting

SOHO 2022 Next Questions: AML

Feat. H. Kantarjian
10:33
Lori Muffly

Next Questions: ALL

11:20
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Orca-T Results in High GVHD-Free and Relapse-Free Surviva…

Feat. S. Srour
15:25
SOHO 2022 Tenth Annual Meeting

Supportive Therapy in CLL

Feat. C. Sun
14:10
SOHO 2022 Tenth Annual Meeting

CLL - Real World Data With Small Molecules

Feat. F. Cymbalista
14:13
SOHO 2022 Tenth Annual Meeting

CLL DEBATE: How Many Drugs Are Needed in 1L CLL?

Feat. A. Mato
15:03
SOHO 2022 Tenth Annual Meeting

CLL DEBATE: Combination Small Molecules vs. Sequencing in CLL - Pro …

Feat. J. Brown
13:53
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Covalent BTK Inhibitors - How Do They Compare in CLL?

Feat. J. Byrd
15:10
SOHO 2022 Tenth Annual Meeting

Clinical Significance of B-Cell Receptor Stereotypy in CLL

Feat. K. Stamatopoulos
10:34
SOHO 2022 Tenth Annual Meeting

SOHO 2022: PACE and OPTIC Trials - Dose Modification Dynamics of Pon…

Feat. H. Kantarjian
16:33
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Asciminib or Ponatinib for Multiresistant CML Patients?

Feat. J. Cortés
14:57
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Immunotherapy - The Way Forward to Maximize TFR in CML?

Feat. D. Rea
13:34
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Beyond TKI Therapy in CML

Feat. M. Copland
09:52
SOHO 2022 Tenth Annual Meeting

SOHO 2022: AGILE - A Phase 3, Global, Randomized, Double-Blind Study…

Feat. A. de la Fuente, C. DiNardo
16:04
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Emerging CAR T-Cell Therapy Approaches in AML

Feat. S. Kenderian
15:39
SOHO 2022 Tenth Annual Meeting

SOHO 2022 AML DEBATE: Is MRD More Prognostic Than Initial Presentati…

Feat. C. Lindsley
16:37
SOHO 2022 Tenth Annual Meeting

SOHO 2022 AML DEBATE: Is MRD More Prognostic Than Initial Presentati…

Feat. M. Heuser
14:41
Farhad Ravandi

Is the Future of AML Therapy All Oral?

14:50
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Non-Intensive Treatment of Elderly/Unfit Patients With AML

Feat. T. Kadia
15:45
SOHO 2022 Tenth Annual Meeting

SOHO 2022: How Do We Overcome Resistance to Venetoclax in AML

Feat. M. Konopleva
15:21
SOHO 2022 Tenth Annual Meeting

SOHO 2022: FLT3-Mutated AML - Triplet vs. Doublet Therapy

Feat. E. Wang
15:13
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Menin Inhibitors in AML

Feat. E. Stein
17:07
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Novel Chemotherapy Can Eliminate the Need for Transplant …

Feat. N. Short
11:49
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Certain Patients With ALL Still Need a Transplant

Feat. J. Ribera, P. Scheinberg
15:52
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Approach to ALL in the Elderly

Feat. M. Luskin
13:46
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Management of Ph+ ALL in 2022

Feat. E. Jabbour
06:35
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Phase II Study of Blinatumomab in Combination With Ponati…

Feat. F. Haddad
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Dual Targeted CAR T-Cells for ALL

Feat. N. Frey
12:49
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Approach to Ph-Like ALL

Feat. E. Curran
16:13
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Blinatumomab in Pediatric ALL

Feat. S. Cooper
12:06
Catherine Coombs

New BTKi in CLL

09:23
SOHO 2022 Tenth Annual Meeting

Novel Agents in CLL

Feat. A. Danilov
11:07
SOHO 2022 Tenth Annual Meeting

SOHO 2022: BCL2i in CLL

Feat. A. Chanan-Khan
08:48
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Childhood CML

Feat. F. Millot
20:12
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Assessment and Management of TKI-Related AOEs in CML

Feat. G. Saglio
13:09
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Non BCR-ABL Mutations in CML - Do They Matter?

Feat. S. Soverini
15:43
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Advances in ALL Diagnosis and Treatment - The NOPHO Exper…

Feat. K. Schmiegelow
09:08
Selina Luger

Approaches to and Use of MRD in ALL

11:13
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Allogeneic CAR T-Cells in ALL

Feat. N. Jain
12:26
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Is TP53-Mutated AML the Same Disease as TP53-Mutated MDS?

Feat. P. Valk
19:33
SOHO 2022 Tenth Annual Meeting

SOHO 2022 Update on CD47 Targeting Antibodies

Feat. N. Daver
20:35
SOHO 2022 Tenth Annual Meeting

SOHO 2022: What Is the Best Strategy for Therapy-Related AML?

Feat. P. Desai